NeurAxis, Inc. NRXS 深 沪
已收盘 02-06 16:00:00 美东时间
4.35
0.000
0.00%
华盛通- 最 高4.45
- 今 开4.40
- 成交量 2.31万股
- 最 低 4.31
- 昨 收 4.35
- 总市值 4633.97万
- 52周最高 6.20
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 1.33
- 委 比 0.00%
- 总股本 1065.28万
- 历史最高 6.93
- 量 比 0.30
- 振 幅 3.22%
- 历史最低 1.33
- 每 手 1
- 风险率 0.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Craig-Hallum Maintains Buy on Neuraxis, Raises Price Target to $8
Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the price target from $7 to $8.
2025-12-23 00:26
NeurAxis Rolls Out New Medical Policy Coverage For Percutaneous Electrical Nerve Field Stimulation
NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced
2025-12-19 21:02
Neuraxis Q3 EPS $(0.24) Misses $(0.17) Estimate, Sales $811.414K Miss $1.000M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 4 percent increase over losses of $(0.25) per share from the same
2025-11-11 06:53
Neuraxis Earnings Preview
Neuraxis (AMEX:NRXS) is gearing up to announce its quarterly earnings on Tuesda...
2025-11-11 00:03
NeurAxis Expands Stock Offering to $6.27 Million
NeurAxis, Inc. ( ($NRXS) ) has issued an announcement. NeurAxis, Inc. has recei...
2025-10-24 20:48
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
NeurAxis has received FDA clearance for its PENFS technology to treat functional abdominal pain and nausea in patients aged 8 and older, marking the first FDA-approved treatment for adults with functional dyspepsia. This expansion includes a new CPT code effective January 1, 2026, enhancing its market reach and offering a non-invasive solution for patients with limited treatment options.
2025-10-24 12:00
NeurAxis Enters Market Offering Agreement with Craig-Hallum
NeurAxis, Inc. ( ($NRXS) ) has provided an update. On August 29, 2025, Neuraxis...
2025-09-02 21:52
Neuraxis Q2 EPS $(0.22) Beats $(0.23) Estimate, Sales $894.086K Miss $967.250M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 47.62 percent increase over losses of $(0.42) per share from the same
2025-08-12 19:05
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
2025-08-12 16:32
